For sufferers with newly identified high-risk endometrial most cancers, postsurgical Keytruda (pembrolizumab) and chemotherapy with or with out radiation didn’t end in an enchancment to disease-free survival (DFS; the time after prognosis a affected person exhibits no indicators of their illness returning) when put next with remedy through chemotherapy with or with out radiation, though a clinically significant profit was skilled by sufferers whose tumors had been mismatch restore poor (dMMR), examine outcomes have proven.
Interim outcomes of the part 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial had been offered through the ESMO Congress 2024.
Examine highlights:
- Though Keytruda plus chemotherapy didn’t enhance total survival in comparison with chemotherapy alone within the normal inhabitants, a clinically significant profit was noticed in sufferers with mismatch restore poor (dMMR) tumors.
- Sufferers with dMMR tumors who obtained Keytruda plus chemotherapy skilled considerably improved disease-free survival (DFS) in comparison with those that obtained chemotherapy alone.
- The trial highlights the significance of mismatch restore (MMR) standing as a predictive biomarker for figuring out sufferers who could profit from Keytruda plus chemotherapy.
Keytruda plus chemotherapy is authorized as a frontline remedy for sufferers with superior or recurrent endometrial most cancers, regardless of mismatch restore (MMR) standing. The choice was primarily based on information exhibiting that the mix lowered the chance of illness development or demise in sufferers with endometrial most cancers no matter MMR standing.
At a median follow-up of 23.9 months within the intent-to-treat (ITT) inhabitants, findings of the protocol-specified third interim evaluation confirmed that the median DFS was not reached in both arm, which means greater than half of the sufferers in every arm had nonetheless not skilled indicators of their illness returning. The 2-year DFS charges had been 75% and 76% within the Keytruda and placebo arms, respectively.
Nonetheless, the median DFS was additionally not reached with Keytruda or placebo in sufferers with dMMR tumors (281 sufferers), however the two-year DFS charges had been 92% and 80%, respectively. In these whose tumors had been mismatch restore proficient (pMMR), the median DFS was not reached in both arm. These two-year DFS charges had been 69% and 75%, respectively.
“The subgroup evaluation by MMR standing suggests a clinically significant profit in DFS for the dMMR subgroup — which is about 25% of the inhabitants — a biomarker inhabitants properly established to have a excessive [tumor mutational burden] and an infected phenotype with elevated PD-L1 expression,” lead examine creator Dr. Toon Van Gorp, a gynecologist oncologist within the Division of Gynecology and Obstetrics at UZ Leuven, in Leuven, Belgium, mentioned in an oral presentation through the assembly.
Presently within the healing intent, adjuvant setting, systemic chemotherapy with or with out radiation is the usual remedy for sufferers with high-risk endometrial most cancers, with five-year DFS charges between 58% and 65% with chemotherapy or chemoradiation.
The coprimary finish factors (foremost outcomes measured on the finish of the examine) had been investigator-assessed DFS and total survival (OS; the time a affected person lives, no matter illness standing) within the intention-to-treat inhabitants.
On the information cutoff date of March 4, 2024, there have been 111 (27%) and 96 (23%) DFS occasions within the Keytruda and placebo arms within the pMMR subgroup in contrast with eight (6%) and 25 (18%) within the dMMR subgroup, respectively. OS information had been immature on the time of the interim evaluation, which means the common variety of deaths didn’t happen in time for information assortment.
Concerning security, any-grade unintended effects occurred in all sufferers in each arms; grade 3 or larger unintended effects occurred in 71% of sufferers on the Keytruda arm in contrast with 63% of these on the placebo arm. There have been no treatment-related deaths.
Therapy discontinuation charges occurred in 24% and 16% of sufferers on the Keytruda and placebo arms; remedy discontinuations led to demise in 3% and 1% of sufferers, respectively. There have been comparable charges between arms of the completely different chemotherapy and radiation discontinuations, Van Gorp famous.
Immune-related unintended effects and infusion reactions occurred in 42% of Keytruda-treated sufferers; these had been grade 3 to five (extreme to lethal) in 10% of sufferers, led to remedy discontinuation in 6%, and led to demise in a single affected person. Within the placebo arm, these charges had been 24%, 4%, and 4%, respectively; no sufferers died due to immune-related unintended effects or infusion reactions.
Within the security inhabitants, unintended effects occurring in no less than 25% of sufferers within the Keytruda and placebo arms comprised alopecia (hair loss, 63%; 65%), anemia (low crimson blood cell depend, 52%; 52%), nausea (44%; 48%), diarrhea (40%; 38%), decreased neutrophil depend (a kind of white blood cell; 35%; 32%), constipation (33%; 30%), peripheral neuropathy (numbness or tingling within the arms and ft; 29%; 34%); decreased white blood cell depend (34%; 28%), arthralgia (joint ache or soreness; 29%; 30%) and fatigue (28%; 30%).
Immune-mediated AEs and infusion reactions occurring in no less than 1% of sufferers in both remedy arm had been according to the identified security profiles of checkpoint inhibitors, Van Gorp defined. These included hypothyroidism, hyperthyroidism, infusion reactions, extreme pores and skin reactions, pneumonitis (irritation of the lung tissue), thyroiditis (irritation of the thyroid gland), colitis (irritation of the colon), adrenal insufficiency and gastritis (irritation of the abdomen lining).
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
